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Abstract
Background: Tumor necrosis factor-α (TNF-α) and its receptors play important roles in the
development and persistence of psoriatic plaques. The antithyroid thioureylenes, propylthiouracil
and methimazole, are effective in the treatment of patients with psoriasis with a significant number
of patients showing clearing or near clearing of their lesions after a several weeks of treatment.
Methods: The present study examined the effect of treatment with propylthiouracil, given in a
dose of 100 mg every 8 hours for 3 months, on the serum levels of TNF-α in 9 patients with plaque
psoriasis.
Results:  Propylthiouracil therapy did not result in a significant decline in serum TNF-α
concentrations.
Conclusions: The findings suggest that the therapeutic effect of propylthiouracil in psoriasis
appears not to be related to any change in the concentration of TNF-α but occurs via an anti-
proliferative mechanism as we have previously speculated.
Background
Psoriasis is a common skin disorder that affects approxi-
mately 2.8 percent of the population and is associated
with morbidity that is comparable that seen with life
threatening disease [1,2]. There is a clearly established
genetic predisposition to the disease [3,4] that is often
triggered by the processing of bacterial, viral or chemical
antigens by skin antigen presenting cells (APC) or Langer-
hans cells [5-9]. The disease is presently believed to be a T
cell disorder that leads to keratinocyte proliferation
[6,10,11]. Plaque formation in the disease reflects both
the effects of accelerated proliferation as well as reduced
apoptosis in proliferated keratinocytes [12,13]. The events
responsible for keratinocyte proliferation have been
extensively reviewed [12]. An important cytokine that is
associated with keratinocyte proliferation in psoriasis is
TNF-α.. TNF-α concentrations are higher in psoriatic
lesions than in unaffected skin of psoriatic patients and
tend to decline with clearing of the lesions after effective
therapy [14-16]. This cytokine is produced by keratinoc-
ytes and leads to an increased expression of cellular adhe-
sion molecules that promote, propagate, and amplify the
immune signals that are responsible for maintaining the
events that lead to psoriasis. Recently introduced thera-
peutic approaches in the management of psoriasis depend
on blocking TNF-α binding to its receptor by using TNF-α
hybrid antibodies. Patients treated with such agents very
often show marked improvement in their disease with
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major clearing in several instances [17-19]. Present day
therapy of the disease is not particularly satisfactory and
the many therapies currently in use are associated with
significant cumulative toxicity [17]. The antithyroid
thioureylenes have been used in the treatment of patients
with hyperthyroidism, particularly Graves' disease, and
have well-defined and very limited toxicity. They have
been used for management of patients with Graves' hyper-
thyroidism for many years without any significant prob-
lems. We and others have described the effectiveness of
these agents in the treatment of patients with plaque pso-
riasis [20-24]. The mechanism of action of these drugs in
psoriasis is unknown but some evidence points to their
ability to act as anti-proliferative agents. The drugs reduce
expression of proliferative cell nuclear antigen (PCNA) a
marker of cellular proliferation [25]. Since plaque forma-
tion is psoriasis is dependent on enhanced proliferation
of keratinocytes particularly in the basal layers of the epi-
dermis any agent that could reduce this critical event in
the pathogenesis of psoriasis would lead to clinical
improvement. The present study was performed to exam-
ine the effect of treatment with propylthiouracil on circu-
lating TNF-α in patients with stable plaque psoriasis.
Methods
Patients
Nine patients (6 male, 3 female) enrolled in the study.
The patients ranged in age from 21 to 65 years (mean ±
SD, 44 ± 16 yrs). None of the patients received photother-
apy or systemic treatment for six weeks and none used
topical therapy other than emollients for six weeks prior
to entry into the study. Patients with allergies to sulfa
medication, pregnant patients, and patients with a known
diagnosis of thyroid dysfunction were excluded from par-
ticipating in the study. All patients signed an informed
consent document approved by the Institutional Review
Board of the University of California, Irvine. The enrolled
volunteers had a complete blood count (CBC) and meas-
urement of thyroid stimulating hormone (TSH) before
starting treatment with propylthiouracil (PTU). CBC and
TSH measurements were obtained again at 2 weeks and
later at 4, 8 and 12 weeks. In addition, blood was removed
for measurement of TNF-α prior to PTU treatment and
again at 2, and 12 weeks later. The blood for TNF-α meas-
urements was collected in tubes containing peptide inhib-
itors, and the serum removed and stored at -70°C until
assayed. Patients were instructed to take 100 mg PTU
every 8 hours for twelve weeks.
Clinical assessment
Clinical evaluation was performed by a single dermatolo-
gist (VSN). Evaluation was performed before enrollment,
and again at 4, 8 and 12 weeks after PTU therapy. Assess-
ment was made using the PASI scoring system.
Measurement of TNF-α
TNF-α levels in serum were measured using a highly sen-
sitive commercially available assay from R&D Systems
(Minneapolis, MN). The assay is a sandwich enzyme
immunoassay (ELISA) with an analytical sensitivity of <
0.2 pg/ml. Intra- and interassay variations are less than
11.3 and 14.7 % respectively. The reference range for nor-
mal volunteers is between 1.2 and 15.3 pg/ml.
Statistical analysis
Statistical analysis was performed using Student's t test for
paired and grouped data. P of <0.05 was considered sig-
nificant.
Results
Clinical scores
All patients showed clinical improvement with PASI
scores declining from 20.1 ± 6.6 to 15.8 ± 4.9 at 4 weeks
(P < 0.02), 11.0 ± 4.8 at 8 weeks (p < 0.0001) and 6.7 ±
4.3 after 12 weeks (p < 0.0001) of PTU therapy.
Serum TNF-α concentrations
Serum TNF-α concentrations were 5.1 ± 2.3 pg/ml before
treatment and did not show significant decline at 2 weeks
(5.1 ± 2.16 pg/ml) and 12 weeks (4.96 ± 2.8 pg/ml) of
treatment.
Side effects
None of the patients experienced any side effects from
PTU treatment. As previously described, white blood
count remained within the normal range during the entire
study, the serum TSH concentration did not rise above the
upper normal range, and neither did any patient develop
signs or symptoms of hypothyroidism.
Discussion
Activated Th1 cells which produce TNF-α and interferon-
γ (IFN-γ) are important in the pathogenesis of psoriasis
[12,26]. These cytokines promote expression of adhesion
molecules such as intercellular adhesion molecule 1
(ICAM-1), and vascular cell adhesion molecule (VCAM)
on keratinocytes and vascular endothelial cells thereby
facilitating migration of additional pro-inflammatory
cells to the area of the psoriatic plaque resulting in the
cytokine cascade that ultimately results in enhanced kerat-
inocyte proliferation and formation of the lesions charac-
teristic of the disease [27] Keratinocytes that have
undergone proliferation, as well as dendritic cells and skin
macrophages, produce TNF-α that leads to an amplifica-
tion of the Th1 role in formation of the psoriatic plaque.
In recent months there have been several studies that have
exploited the use of designer antibodies directed against
the binding of TNF-α to its receptor (etanercept) [19] or
that prevent the association of leucocyte-function associ-
ated antigen (LFA) and ICAM-1 (efalizumab) [28]. ThereBMC Dermatology 2004, 4 http://www.biomedcentral.com/1471-5945/4/4
Page 3 of 4
(page number not for citation purposes)
is significant clinical improvement in patients treated with
these agents. There is, however, loss of clinical benefit
after the drugs are stopped and a small proportion of
patients develop antibodies to the agents which is likely to
limit there efficacy with repeated use. The antithyroid
thioureylenes, in contrast, are easily administered oral
medications that cost a mere fraction of the amount nec-
essary to treat a patient with psoriasis with a designer anti-
body. The mechanism of action of antithyroid
thioureylenes in psoriasis is unclear. Based on our previ-
ous observations, the drugs do not appear to produce any
change in circulating IL-2 receptor or ICAM-1 [29], and
lack effects on pro-inflammatory cytokines such as IL-12
or anti-inflammatory cytokines such as IL-10 [30]. The
drugs do, however, produce a significant decline in mark-
ers of cellular proliferation, particularly in proliferative
nuclear cell antigen (PCNA) expression [25] suggesting
that the principal therapeutic benefit of these drugs in
psoriasis may be exerted via their anti-proliferative effect.
Conclusions
The lack of any effect on circulating TNF-α in this study
argues against any effect of propylthiouracil on keratinoc-
yte production of TNF-α. Since PTU and other antithyroid
thioureylenes cause a decrease in keratinocyte prolifera-
tion one would expect a fall in TNF-α concentration after
use of these agents in patients showing significant clinical
improvement. The fact that this did not occur requires fur-
ther investigation.
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